

# ForwardHealth **ALERT**

Wisconsin serving you



**TO**

All Providers, HMOs and Other Managed Care Programs

**REGARDING**

Revoked Emergency Use Authorization for Bamlanivimab When Administered Alone

## Revoked Emergency Use Authorization for Bamlanivimab When Administered Alone

On April 16, 2021, the United States Food and Drug Administration revoked the emergency use authorization for Bamlanivimab when administered alone. As a result, for dates of services on and after April 17, 2021, the following procedure codes will **not** be reimbursed:

- Q0239 (Bamlanivimab-xxxx)
- M0239 (Bamlanivimab-xxxx infusion)

## Bamlanivimab Combination Procedure Codes Remain Covered

Alternative monoclonal antibody therapies are still appropriate for treating COVID-19 patients and providers may continue using these authorized therapies when administered together.

The following procedure codes are not affected by the revocation of Bamlanivimab's emergency use authorization and **will continue to be reimbursed**:

- Q0245 (Injection, bamlanivimab and etesevimab, 2100 mg)
- M0245 (Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring)
- Q0243 (Injection, casirivimab and imdevimab, 2400 mg)
- M0243 (Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring)